Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc.

Orphan Drug Designation is a critical regulatory pathway that supports the development of treatments for rare diseases affecting fewer than 200,000 individuals in the U.S. Rett Syndrome ...

Orphan Drug Designation is a critical regulatory pathway that supports the development of treatments for rare diseases affecting fewer than 200,000 individuals in the U.S. Rett Syndrome ...

Neuren Pharmaceuticals (ASX:NEU) is focused on neurodevelopmental disorders and rare disease drug development.In this ...

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) have been assigned an average recommendation of “Buy” from the eight research firms that are presently covering the company, ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Merus N.V. is a better investment based on AAII's A+ Investor grades, ...

More than a half million dollars was raised at the Schreiber Center for Pediatric Development’s 41st Annual Gala.

We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how ...

Let's talk about menopause, AI, Alzheimer's and more health topics at South by Southwest, with some lab brains and nature ...

Bank of New York Mellon Corp lowered its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL – Free Report) by 2.1% during the 4th quarter, according to the company in its most recent disclosure with the ...

a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to ...